GlucoTrack, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Erik Emerson
- Full Time Employees
- 15
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Address
- 301 Route 17 North Rutherford NJ United States of America 07070
- IPO Date
- Apr 25, 2013
- CIK
- 0001506983
- Website
- glucotrack.com
- Similar Companies
- Business
- GlucoTrack, Inc. (Nasdaq: GCTK) develops and commercializes novel implantable technologies for continuous blood glucose monitoring to improve glycemic management for people living with diabetes; its primary product candidate is a fully implantable continuous blood glucose monitor (CBGM) featuring a sensor longevity of three years, real-time blood glucose measurement from the subclavian vein, no external wearable components, and minimal calibration requirements. The company, founded in 2001 and headquartered in Rutherford, New Jersey, previously known as Integrity Applications, Inc. until its rebranding in November 2021, targets Type 1 and insulin-dependent Type 2 diabetes patients with its investigational CBGM system, which has advanced through preclinical animal studies, a first human clinical study demonstrating safety and accuracy, and ongoing preparations for multicenter feasibility trials in Australia and a U.S. pilot study pending FDA Investigational Device Exemption approval in late 2025. Recent developments include securing $16.3 million in funding proceeds from November 2024 through March 2025 to support clinical milestones, repurchasing over 90% of its Series A Warrants in June 2025 as part of capital structure optimization following a $10 million public offering, achieving ISO 13485:2016 certification for medical device quality standards, expanding research into epidural glucose monitoring applications, strengthening its leadership and advisory boards with key appointments in clinical, regulatory, and financial expertise, and presenting clinical data at major conferences such as ATTD 2025.
Company News
Glucotrack Achieves Key Compliance Milestone and Advances Strategic Transformation
E.F. Hutton & Co. Acts as Exclusive Financial Advisor for $5.5 Million Financing for Glucotrack
Glucotrack Announces $5.5 Million Financing
Lōkahi Therapeutics™ ai² Futures Lab™ Changes How Biopharma Builds a Pipeline
Lōkahi Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration
E.F. Hutton & Co. Serves as Exclusive Financial Advisor on Strategic Business Combination Between Glucotrack and Lōkahi Therapeutics and Exclusive Placement Agent for Approximately $5.7 Million Convertible Note Financing
Glucotrack, Inc. and Lōkahi Therapeutics™ Announce Strategic Financing Support from E.F. Hutton & Co. in Connection with Their Recently Completed Business Combination and Future Capital Markets Initiatives
UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform
Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association's 2026 Scientific Sessions
Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology
Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology
Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Short Interest in GlucoTrack, Inc. (NASDAQ:GCTK) Increases By 53.5%
Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
Glucotrack to Present at LSI USA '26 Medtech Innovation Summit
Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform